The worldwide emergence of multi-drug resistant bacterial strains is a growing concern, especially infections caused by Pseudomonas spp. and P. aeruginosa in particular. P. aeruginosa is an opportunistic pathogen with innate resistance to many antibiotics and disinfectants including anti-pseudomonal Penicillins, Ceftazidime, Carbapenems, Aminoglycosides and Ciprofloxacin 1 . Infections due to P. aeruginosa are seldom encountered in healthy adults; but in the last two decades, the organism has become increasingly recognized as the etiological agent in patients with impaired immune defenses 2 . Pseudomonads are more versatile than Enterobacteriaceae in acquiring drug resistance by various mechanisms. The production of extended-spectrum beta-lactamases (ESBLs) confers resistance at various levels to expanded spectrum Cephalosporins 3 . These enzymes are encoded by different genes located on either chromosomes or plasmids 4 . ESBL-producing bacteria may not be detectable by the routine disk diffusion susceptibility test, leading to inappropriate use of antibiotics and treatment failure.

Several different methods have been suggested for the detection of ESBLs in clinical isolates 5 , such as disk approximation or double disk synergy, modified double disc test (MDDT), CLSI phenotypic confirmatory method, E-test ESBL strips, three dimensional test, Vitek system, etc. While each of these tests has merit, none are able to detect all of the ESBLs encountered. Disk approximation or double disk synergy is one of the currently available and most widely used techniques for the detection of ESBLs 6 .

Although bacterial resistance to the beta-lactam drugs and the mechanisms leading to this resistance have become a primary focus for clinicians and researchers, until recently, only a few studies have been carried out to detect ESBL bacteria in Bangladesh. Further, routine ESBL phenotype screening is not yet practiced in Bangladesh. The present study was conducted with an aim to detect the prevalence of ESBL-producing Pseudomonas spp. isolated from clinical samples of two tertiary care hospitals in Bangladesh.

Table 1 shows the frequency distribution of Pseudomonas spp. with the number of ESBL-positive cases. Of 82 strains of Pseudomonas spp. tested for ESBL, 31 (37.8%) were found as ESBL-positive with the highest frequency (75%) from urine, followed by throat (50%), pus (35%), aural (33.3%) wound (26.3%) and sputum (25%).

Distribution of Pseudomonas species and serotypes of Pseudomonas aeruginosa with ESBL positive strains are shown in Table 2. Of 120 Pseudomonas isolates, 82 were identified at the species level based on their distinct biochemical and pigment production characteristics 7 . Pseudomonas aeruginosa, Pseudomonas fluorescens, Stenotrophomonas maltophilia, Ralstonia pickettii and Pseudomonas alkaligenes were detected at a frequency of 74 (90.2%), 2 (2.45%), 2 (2.45%), 2 (2.45%) and 2 (2.45%) respectively. Of 74 Pseudomonas aeruginosa isolates, 29 (39.2%) were ESBL positive. Serotyping of Pseudomonas aeruginosa revealed 25 as A,C,H,I,L (polyvalent group I), 17 as B,J,K,M (polyvalent group II) and 32 as D,E,F,G,N (polyvalent group III).

Antimicrobial susceptibility pattern revealed that Imipenem was the most effective drug against Pseudomonas spp. with susceptibility of 93.3%, followed by Tobramycin (66.7%), Amikacin (63.7%) and Gentamycin (60%). Susceptibility of Pseudomonas spp. to 3rd generation Cephalosporins ranged from 43.3 to 46.7% and Aminoglycosides had better efficacy than 3rd generation Cephalosporins (Table 3).

ESBL-producing organisms pose unique challenges to clinical microbiologists, clinicians, infection control professionals and scientists engaged in finding new antibacterial molecules. ESBL-producing strains are usually found in those hospitals where antibiotic use is frequent and the patients are in critical condition. In the present study, 120 Pseudomonas spp. were isolated from 600 bacterial cultures with Pseudomonas aeruginosa as the most frequent (90.2%) species accounting for 18% of clinical cases. The prevalence of P. aeruginosa is consistent with the findings of Wiblin (1997), who documented 16% prevalence for various infections 10 .

The rates of ESBL-positive Pseudomonas spp. (37.8%) and Pseudomonas aeruginosa (39.2%) found in our study were in accordance with similar studies conducted in Bangladesh and other South East Asian countries 3 4 11 12 13 , although low detection rates of 3.7% to 7.7% were noted in studies conducted by others 14 15 . Infection patterns, hospital infection control measures and antibiotic policy are all important considerations for variation of detection rates in different hospitals. Of note, we also found two ESBL-negative P. fluorescens species, and a recent study has shown that these species produce metallo-beta-lactamase, another very important beta-lactam inhibitor that can act as a reservoir of multidrug resistance element that may be transferred to successful P. aeruginosa clones 16 .

The distribution of ESBL-positive Pseudomonas spp. in different samples and its resistance to 3rd generation Cephalosporins is comparable to the findings of Aggarwal et al. 4 . This resistance is due to the hydrolysis of the β-lactam ring by the action of β-lactamase enzymes. Other mechanisms for drug resistance to the β-lactam group of antibiotics are loss of outer membrane protein, production of class C AmpC β-lactamases and altered target sites. ESBL enzymes are inhibited by β-lactamase inhibitors, particularly Clavulanic acid and Sulbactam. Hence the use of β-lactam/β-lactamase inhibitor combination therapy may be an alternative to 3rd generation Cephalosporins, but the effect of this combination varies depending on the subtype of ESBL present 17 .

Imipenem was found to be the most efficacious drug against Pseudomonas spp. in our study, which is in accordance with findings of Ullah et al. 13 ; however, notably in our study, Imipenem underperformed compared to the 100% susceptibility found in ESBL-producing gram-negative isolates, including P. aeruginosa, in different studies 13 18 . Decreased susceptibility to Imipenem is a matter of great concern for treating infections caused by Pseudomonas aeruginosa and indicates the urgent need for improved infection control strategies.

ESBL-producing Pseudomonas spp., and P. aeruginosa in particular, were found to be frequent isolates from two tertiary care hospitals in Bangladesh with limited susceptibility to antimicrobials. Further, decreased susceptibility to Imipenem is a matter of great concern as it is the drug of choice in the treatment of Pseudomonad infection.

The authors declare that they have no competing interests.

SB conceived the research idea and performed the laboratory work. KFA and NB helped in sample collection and preparation of the manuscript. JAH and PH helped in designing the study and supervision of the work. MAS contributed intellectual thought, final revision and editing of the manuscript. All authors have read and approved the submitted version of manuscript.